Answers are grounded in this paper and cite their sources.
This Viewpoint assesses the US Food and Drug Administration’s priority review voucher program to encourage development of drugs to treat neglected tropical diseases or rare pediatric disease and recommends improvements to the program.
No takes yet. Share an insight, caveat, or question.
Kesselheim et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: